Your browser is no longer supported. Please, upgrade your browser.
BriaCell Therapeutics Corp.
Index- P/E- EPS (ttm)- Insider Own22.56% Shs Outstand6.70M Perf Week-10.57%
Market Cap22.10M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float3.90M Perf Month-24.66%
Income- PEG- EPS next Q- Inst Own34.13% Short Float3.72% Perf Quarter-29.34%
Sales- P/S- EPS this Y- Inst Trans- Short Ratio0.13 Perf Half Y-24.09%
Book/sh- P/B- EPS next Y- ROA- Target Price- Perf Year-74.48%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range2.81 - 7.51 Perf YTD-20.86%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-56.08% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low17.23% ATR0.38
Employees- Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)45.65 Volatility8.94% 11.56%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.25 Prev Close3.15
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume1.11M Price3.30
Recom- SMA20-4.73% SMA50-8.71% SMA200-43.67% Volume274,950 Change4.76%
Apr-25-21 05:18AM  
Apr-21-21 08:00AM  
Apr-15-21 06:00PM  
Apr-12-21 01:45PM  
Mar-30-21 06:30AM  
Feb-26-21 02:24PM  
BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing approaches for the management of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.